Liver Tumours programme overview

One of the major topics of discussion at the EASL Congress 2023 will be Nonalcoholic Steatohepatitis (NASH) and its association with liver cancer. NASH is rapidly becoming one of the leading causes of liver cancer worldwide, and it is important to stay up-to-date on the latest advancements in the field. We will have a dedicated session to provide you with the latest data and communication surrounding NASH and liver cancer.

Additionally, the congress will cover recent advancements in systemic treatment for hepatocellular carcinoma (HCC), specifically immunotherapy. These treatments are currently being used in advanced stages of HCC, but there is potential for them to be used as adjuvant treatment after curative treatment for HCC. It is important to stay current on these emerging advancements in the management of liver cancer patients.

Participants will hear from experts who will discuss what will shape the field in future years. The sessions will also provide a great opportunity for delegate networking and discussion; and for industry stakeholders to showcase results.